Finance

Lists
Why is INO up ၁၆.၄၃%?
Dive Deeper
INO:NASDAQ
Inovio Pharmaceuticals Inc
၁.၆၃ US$
+၁၆.၄၃%
(+၀.၂၃) 1D
၁.၆၇ US$
+၂.၄၄% (+၀.၀၄၀)
After hours
Closed: နို ၁၇, GMT-၅ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
၁.၃၈ US$
High
၁.၆၄ US$
Low
၁.၃၇ US$
Mkt. cap
၃၀.၅၃ ကုဋေ
Avg. vol.
၁.၉၅ ကုဋေ
Volume
၁.၅၈ ကုဋေ
52-wk high
၂.၇၂ US$
52-wk low
၀.၅၇ US$
EPS
-၀.၈၀ US$
Beta
၁.၇၁
Shares outstanding
၁၈.၇၃ ကုဋေ
No. of employees
၁၁၂
Open
၁.၃၈ US$
High
၁.၆၄ US$
Low
၁.၃၇ US$
Mkt. cap
၃၀.၅၃ ကုဋေ
Avg. vol.
၁.၉၅ ကုဋေ
Volume
၁.၅၈ ကုဋေ
52-wk high
၂.၇၂ US$
52-wk low
၀.၅၇ US$
EPS
-၀.၈၀ US$
Beta
၁.၇၁
Shares outstanding
၁၈.၇၃ ကုဋေ
No. of employees
၁၁၂
News stories
From web sources and news partners
The Business Journals
The Business Journals
·
ပြီးခဲ့သည့် ၁၁ နာရီ
After 43 years, Inovio gets its first FDA-approved drug in 'milestone' decision
MarketWatch
MarketWatch
·
ပြီးခဲ့သည့် ၁ ရက်
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees၁၁၂
Founded၁၉၉၉
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current ၁.၆၃ US$
၈.၀၀ US$ (+၃၉၀.၈၀%)
Average
၆.၃၃ US$ (+၂၈၈.၃၄%)
Lowest
၅.၀၀ US$ (+၂၀၆.၇၅%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
၅.၀၀ US$
+၂၀၆.၇%
11/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
၆.၀၀ US$
+၂၆၈.၁%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
၈.၀၀ US$
+၃၉၀.၈%
11/06/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
၁၃.၀၀ US$
+၆၉၇.၅%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
-
-
-
၂.၉၉ သိန်း
Cost of goods sold
၁.၀၃ ကုဋေ
၁.၄၁ ကုဋေ
၁.၀၈ ကုဋေ
-
Cost of revenue
၁.၀၃ ကုဋေ
၁.၄၁ ကုဋေ
၁.၀၈ ကုဋေ
-
Research and development expenses
-
-
-
၁.၀၆ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၇.၂၂ သန်း
၇.၈၈ သန်း
၇.၈၀ သန်း
၉.၂၁ သန်း
Operating expense
၇.၂၂ သန်း
၇.၈၈ သန်း
၇.၈၀ သန်း
၁.၉၈ ကုဋေ
Total operating expenses
၁.၇၅ ကုဋေ
၂.၁၉ ကုဋေ
၁.၈၆ ကုဋေ
၁.၉၈ ကုဋေ
Operating income
-၁.၇၅ ကုဋေ
-၂.၁၉ ကုဋေ
-၁.၈၆ ကုဋေ
-၁.၉၅ ကုဋေ
Other non operating income
၂.၁၂ ကုဋေ
၄.၁၄ သန်း
၁.၂၇ ကုဋေ
-၃.၀၂ ကုဋေ
EBT including unusual items
၃.၇၆ သန်း
-၁.၉၇ ကုဋေ
-၆.၀၁ သန်း
-၄.၉၂ ကုဋေ
EBT excluding unusual items
၃.၇၅ သန်း
-၁.၉၅ ကုဋေ
-၅.၅၃ သန်း
-၄.၉၃ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
၃.၇၆ သန်း
-၁.၉၇ ကုဋေ
-၆.၀၁ သန်း
-၄.၉၂ ကုဋေ
Net profit margin
-
-
-
-၁၆,၄၆၁.၉၀%
Earnings per share
-၀.၂၈
-၀.၃၁
-၀.၂၄
-၀.၂၃
Interest and investment income
၄.၄၉ သိန်း
၄.၄၀ သိန်း
၃.၆၄ သိန်း
၃.၅၆ သိန်း
Interest expense
-
-
-
-
Net interest expenses
၄.၄၉ သိန်း
၄.၄၀ သိန်း
၃.၆၄ သိန်း
၃.၅၆ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၇၁ ကုဋေ
-၂.၁၆ ကုဋေ
-၁.၈၃ ကုဋေ
-၁.၉၂ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ